Inclusion Criteria:

          -  First or second recurrence of previously histologically confirmed glioblastoma (grade
             4 astrocytoma)

               -  NOTE: gliosarcomas and other grade 4 astrocytoma variants (e.g., giant cell) may
                  be included, primitive neuroectodermal tumor (PNET) variants are excluded; grade
                  4 oligodendrogliomas or oligoastrocytomas are specifically excluded

          -  Prior craniotomy and gross total or sub-total resection of tumor at this recurrence
             NOTE: biopsy of this recurrence alone without attempt at resection does not meet this
             inclusion criteria (i.e. craniotomy and resection is still required).

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2

          -  Absolute neutrophil count (ANC) >= 1500/uL

          -  Monocytes >= 300/uL

          -  Platelets (PLT) >= 100,000/uL

          -  Hemoglobin (HgB) >= 9.0 g/dL

          -  Total bilirubin =< 1.5 x upper limit of normal (ULN)

          -  Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 3
             x ULN

          -  Creatinine =< 1.5 x ULN

          -  Negative pregnancy test done =< 7 days prior to registration, for persons of
             childbearing potential only

          -  Ability to understand and willingness to sign written informed consent

          -  Willing to return to Mayo Clinic in Rochester, Minnesota for follow-up

          -  Willing to provide tissue and blood samples for mandatory correlative research
             purposes

          -  Fixed or decreasing dose of corticosteroids (or no corticosteroids) >= 7 days prior to
             registration

        Exclusion Criteria:

          -  Prior treatment

               -  Current or prior treatment for this cancer with immunotherapy and/or any other
                  investigational agents

               -  Surgery =< 2 weeks prior to registration

               -  Radiotherapy =< 12 weeks prior to registration

               -  Treatment with bevacizumab or any cytotoxic chemotherapy =< 8 weeks prior to
                  registration

          -  Any of the following

               -  Pregnant persons

               -  Nursing persons

               -  Persons of childbearing potential who are unwilling to employ adequate
                  contraception

          -  Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment
             of the investigator, would make the patient inappropriate for entry into this study or
             interfere significantly with the proper assessment of safety and toxicity of the
             prescribed regimens

          -  Immunocompromised patients (other than that related to the use of corticosteroids)
             including patients known to be human immunodeficiency virus (HIV), human T-cell
             lymphotropic virus (HTLV), hepatitis B (HepB), or hepatitis C (HepC) positive

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  History of other malignancy other than glioma

               -  EXCEPTIONS: non-melanotic skin cancer, carcinoma-in-situ of the cervix, or
                  systemic cancer that has been in documented remission for > 10 years

               -  NOTE: if there is a history or prior malignancy, they must not be receiving other
                  specific treatment for their cancer

          -  History of myocardial infarction =< 180 days (6 months), or congestive heart failure
             requiring use of ongoing maintenance therapy for life-threatening ventricular
             arrhythmias

          -  Active infection =< 5 days prior to registration or fever >/= 38 degrees Celsius (C)
             within 5 days prior to registration

          -  History of tuberculosis or positive purified protein derivative (PPD) test

          -  Inability or unwillingness to have magnetic resonance imaging (MRI) scans performed
             (e.g. cardiac pacemaker-dependent)